Scarica l'app Stockscreener
6.07
5.93%
0.34
Dopo l'orario di chiusura:
6.07
Precedente Chiudi:
$5.73
Aprire:
$5.87
Volume 24 ore:
6.49M
Relative Volume:
3.26
Capitalizzazione di mercato:
$505.00M
Reddito:
$14.20M
Utile/perdita netta:
$-49.59M
Rapporto P/E:
-7.2056
EPS:
-0.8424
Flusso di cassa netto:
$-35.25M
1 W Prestazione:
+31.96%
1M Prestazione:
+65.85%
6M Prestazione:
+25.15%
1 anno Prestazione:
+356.39%
Intervallo 1D:
$5.40
$6.24
Intervallo di 1 settimana:
$4.305
$7.07
Portata 52W:
$1.32
$7.07
Opus Genetics Inc Stock (IRD) Company Profile
Nome
Opus Genetics Inc
Settore
Industria
Telefono
248-681-9815
Indirizzo
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
6.07 | 476.71M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-03-16 | Iniziato | Oppenheimer | Outperform |
| 2026-01-20 | Iniziato | BTIG Research | Buy |
| 2025-12-10 | Iniziato | B. Riley Securities | Buy |
| 2025-11-25 | Iniziato | Piper Sandler | Overweight |
| 2025-10-29 | Iniziato | Wedbush | Outperform |
| 2025-10-16 | Iniziato | Chardan Capital Markets | Buy |
| 2025-04-11 | Iniziato | Craig Hallum | Buy |
| 2024-11-13 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Opus Genetics Inc Borsa (IRD) Ultime notizie
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Opus Genetics (NASDAQ: IRD) Plans Phase 3 Trial for OPGx-BEST1 in 2027 Following Promising Cohort 1 Results - Kalkine Media
Opus Genetics: A Resounding Study Success Merits A Higher Valuation (NASDAQ:IRD) - Seeking Alpha
IRD Maintained by Wedbush -- Price Target Raised to $13.00 - GuruFocus
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $10 to $20 - Moomoo
Chardan Raises Price Target on Opus Genetics to $16 From $13, Keeps Buy Rating - marketscreener.com
Opus Genetics Stock Jumps 32% on Five-Patient Eye-Therapy Data—What IRD Must Prove Next - TechStock²
JonesTrading Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wedbush raises Opus Genetics stock price target on FDA alignment By Investing.com - Investing.com Nigeria
IRD Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
Opus Genetics Shares Jump 30% as Low-Dose Gene Therapy Shows Vision Gains in Retinal Disease Trial - finance.biggo.com
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy TrialSlideshow - Seeking Alpha
Opus Genetics Shares Rise After Reporting Vision Improvement in Phase 1/2 OPGx-BEST1 Trial - marketscreener.com
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial - Stocktwits
Wedbush raises Opus Genetics stock price target on FDA alignment - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
IRD: OPGX-BEST1 gene therapy showed robust safety and efficacy, supporting phase III advancement - TradingView
IRD Reiterates by BTIG -- Price Target Maintained at $12.00 - GuruFocus
Why Opus Genetics (IRD) Stock Is Up Today - Quiver Quantitative
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Opus Genetics Reports Positive Phase 1/2 Data for Gene Therapy OPGx-BEST1 - Minichart
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says - Benzinga
IRD: OPGX-BEST1 Phase 1/2 trial showed strong efficacy, safety, and FDA alignment for pivotal development - TradingView
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data, Targets Potential Phase 3 Dosing in 2027 - Yahoo Finance
IRD: OPGX-BEST1 gene therapy showed robust safety and functional gains, supporting pivotal trial advancement - TradingView
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
Opus Genetics Reveals Interim Phase 1/2 BIRD-1 Trial Outcomes for OPGx-BEST1 - Kalkine Media
IRD Stock Jumps As Traders Target Gene Therapy Catalyst - timothysykes.com
IRD Stock Eyes Webcast Catalyst As Gene Therapy Data Nears - StocksToTrade
IRD Maintained by Chardan Capital -- Price Target at $13.00 - GuruFocus
Opus Genetics Reports Positive Phase 1/2 Data for OPGx-BEST1 in BEST1-Related Retinal Disease - Eyewire+
Opus Genetics Reports Vision Improvement in Phase 1/2 OPGx-BEST1 Trial - marketscreener.com
Opus Genetics Reports Positive OPGx-BEST1 Phase 1/2 Data - TipRanks
IRD Looks 1451.8% Overvalued on GF Value™ - GuruFocus
Opus Genetics reports positive low‑dose Cohort 1 OPGx-BEST1 Phase 1/2 data; advances to higher-dose Cohort 2 - TradingView
Opus Genetics Reports Positive Interim Phase 1/2 Results for OPGx-BEST1 in BEST1-Related Retinal Diseases - Quiver Quantitative
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027 - Yahoo Finance
Opus Genetics Director Cam Gallagher Exercises Warrant for 784,314 Shares, Enters 180-Day Lock-Up - Kalkine Media
Opus Genetics (IRD) director adds shares, accepts 180-day lock-up - Stock Titan
Opus Genetics (IRD) CFO stock sale mixes tax withholding and 10b5-1 plan - Stock Titan
Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026. - Pluang
Opus Genetics stock rating reaffirmed at Buy by H.C. Wainwright - Investing.com Canada
Missed Opus Genetics' 130% Run? The Story Isn't Over Yet - RTTNews
LifeSci Capital Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Opus Genetics to Present Topline Phase 1/2 OPGx-BEST1 Gene Therapy Data on September 9 - Quiver Quantitative
Opus Genetics Plans OPGx-BEST1 Data Webcast Sept. 9 | IRD Stock News - Stock Titan
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data - Yahoo Finance
Why is Opus Genetics stock rallying today? By Investing.com - Investing.com Nigeria
Why is Opus Genetics stock rallying today? - Investing.com
IRD | Opus Genetics, Inc. Common FinancialsRevenue Breakdown - quiverquant.com
Citizens reiterates Opus Genetics stock rating on Viatris partnership potential By Investing.com - Investing.com Nigeria
Opus Genetics Inc Azioni (IRD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):